Journal
BONE MARROW TRANSPLANTATION
Volume 40, Issue 3, Pages 239-243Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bmt.1705712
Keywords
autologous bone marrow transplant; anaplastic large-cell lymphoma; peripheral T-cell lymphoma
Categories
Ask authors/readers for more resources
The role of high-dose therapy and autologous stem cell transplantation ( ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma ( 21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) a re 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T- cell lymphoma are needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available